Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Olaparib · Lynparza, AZD-2281

Small molecule · Inhibitor of PARP1, PARP2 and PARP3 · developed by Astrazeneca

Approved FDA, Dec 2014

AZN Developer

1 Registered trials

What is Olaparib?

Olaparib is a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes PARP1, PARP2, and PARP3. It inhibits PARP enzymatic activity and increases PARP-DNA complex formation, leading to DNA damage and cancer cell death.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Lynparza, AZD-2281, KU-0059436, AZ-2281, Olanib, Olaparix
Drug type: Small molecule
Targets: PARP1, PARP2, PARP3, BRCA1 (biomarker), BRCA2 (biomarker), ATM (biomarker)
Mechanism: Inhibitor of PARP1, PARP2 and PARP3
Pathways: DNA repair, homologous recombination repair
Therapy area: Oncology
Developer: Astrazeneca (AZN)
FDA status: Approved as Lynparza (December 19, 2014), NDA206162 · FDA label
UNII: WOH1JD9AR8

✅ FDA-approved uses

Maintenance treatment of deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary
Maintenance treatment in combination with bevacizumab of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer with homologous reco
Maintenance treatment of deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary
Adjuvant treatment of deleterious or suspected deleterious BRCA-mutated, HER2-negative high risk early breast cancer after neoadjuvant or adjuvant che
Treatment of deleterious or suspected deleterious BRCA-mutated, HER2-negative metastatic breast cancer after chemotherapy

From the indications section of the FDA label (version of Jul 10, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02446600	Phase 3	Fallopian Tube Clear Cell Adenocarcinoma	Active not recruiting	AZN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube Clear Cell AdenocarcinomaFallopian Tube Transitional Cell CarcinomaFallopian Tube Undifferentiated CarcinomaOvarian Clear Cell AdenocarcinomaOvarian Endometrioid TumorOvarian Seromucinous CarcinomaOvarian Serous TumorOvarian Transitional Cell CarcinomaOvarian Undifferentiated CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Ovarian Endometrioid AdenocarcinomaRecurrent Primary Peritoneal Carcinoma

Other drugs acting on PARP1 / PARP2 / PARP3

Niraparib FDA approved 2X-121 Phase 2 EIK1004 Investigational IMP1734 Investigational Senaparib Investigational Veliparib Phase 1

More from Astrazeneca

Acalabrutinib FDA approved Anifrolumab FDA approved Benralizumab FDA approved Camizestrant FDA approved Durvalumab FDA approved Tremelimumab FDA approved Actinium Ac 225 FPI-2068 Phase 1 Adavosertib Phase 2 AZD0240 Phase 1 AZD4144 Phase 1 AZD4916 Phase 1 AZD5492 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Olaparib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z